AGILE THERAPEUTICS INC (AGRX) Stock Price, Forecast & Analysis
NASDAQ:AGRX • US00847L3087
AGRX Key Statistics, Chart & Performance
The current stock price of AGRX is 0.6022 USD. In the past month the price decreased by -25.49%. In the past year, price decreased by -94.62%.
AGRX Technical Analysis
AGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AGRX. AGRX has a bad profitability rating. Also its financial health evaluation is rather negative.
AGRX Financial Highlights
Over the last trailing twelve months AGRX reported a non-GAAP Earnings per Share(EPS) of -13.33. The EPS increased by 97.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.26% | ||
| ROA | 75.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGRX Forecast & Estimates
7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022.
For the next year, analysts expect an EPS growth of 93.92% and a revenue growth 101% for AGRX
AGRX Ownership
AGRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.49 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 21.19 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.52 | 302.459B | ||
| PFE | PFIZER INC | 8.94 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 122.756B | ||
| ZTS | ZOETIS INC | 18.53 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.32 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AGRX
Company Profile
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
Company Info
AGILE THERAPEUTICS INC
500 College Road East, Suite 310
Princeton NEW JERSEY 08540 US
CEO: Alfred Altomari
Employees: 22
Phone: 16096831880
AGILE THERAPEUTICS INC / AGRX FAQ
Can you describe the business of AGILE THERAPEUTICS INC?
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
What is the current price of AGRX stock?
The current stock price of AGRX is 0.6022 USD. The price increased by 10.11% in the last trading session.
Does AGRX stock pay dividends?
AGRX does not pay a dividend.
How is the ChartMill rating for AGILE THERAPEUTICS INC?
AGRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about AGILE THERAPEUTICS INC (AGRX) stock?
7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022.